ArticleJAMA network open2026
Prevalence of Over-the-Counter and Prescription Medication Use in the US.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Acyclic cucurbituril as sequestrant for acetaminophen.Chemical communications (Cambridge, England) · 2026Article
- Using prescription drug data for timely assessments of state insurance coverage rates: a validation study.Health affairs scholar · 2026Article
- Medication profiles of patients undergoing dental treatment under general anesthesia or sedation in special needs dentistry.Frontiers in oral health · 2026Article
- Safety assessment for ibuprofen using disproportionality analysis: a decade of data from the Romanian national pharmacovigilance system.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: In the US, reliance on over-the-counter (OTC) and prescription medications has important public health implications. Understanding the prevalence of medication use, overall and by specific medication, aids in regulatory decision-making and pharmacoeconomic evaluations and informs measures of benefits and risks. Objective: To estimate the current prevalence of OTC and prescription medication use in the US adult population. Design, Setting, and Participants: This survey study analyzed data collected via a population-based, online survey of the US adult population (June 2023 to April 2024). Participants were volunteer online panelists aged 18 years and older. Exposure: Use of any OTC or prescription medication. Main Outcomes and Measures: The primary outcome was prevalence of OTC and prescription medication use (overall and by specific medication), stratified by sex and age. Prevalence estimates were generated by calculating the proportion of the population reporting the key outcomes. Results: Of the 21 000 participants, 11 171 (53.2%) were female, and the mean (SD) age was 47.9 (17.5) years. Past-7-day prevalence of OTC or prescription medication use was 62.3% (13 073 individuals). The use of 5 or more medications was reported by 3425 participants (16.3%), and 690 (3.3%) reported taking 10 or more medications. Although use was higher among female individuals (7442 participants [66.6%]) than among male individuals (5631 participants [57.3%]), the patterns of increasing use and increasing number of medications with age were similar. The past-7-day prevalence of OTC medication use (9657 participants [46.0%]) was similar to that of prescription medications (9719 participants [46.3%]). Acetaminophen (6184 participants [29.4%]), ibuprofen (4693 participants [22.3%]), and aspirin (3323 participants [15.8%]) were the most reported medications used in the past 7 days. Six of the 10 most prevalent medications reported were available OTC. The most reported prescription medications were atorvastatin (1342 participants [6.4%]), lisinopril (1163 participants [5.5%]), levothyroxine (1086 participants [5.2%]), and amlodipine (965 participants [4.6%]). Conclusions and Relevance: In this 2023 to 2024 study, nearly 2 of 3 US adults reported medication use in the past 7 days. Past-7-day prevalence of OTC and prescription medication use was similar, demonstrating the reliance on these therapies and highlighting the importance of accessibility. Medication-specific prevalence allows for a better understanding of actual use and the ability to estimate potential benefits and risks associated with medication access or regulatory changes. Continued monitoring is necessary to measure the benefits and risks of regulatory decisions or other market changes that may affect medication access or use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.